Biopharma AI
ByIs AbCellera Biologics Building a Durable AI Antibody Discovery Engine as Pharma Partnerships Signal Multi-Billion-Dollar Potential?
Executive Summary AbCellera Biologics has established itself as a global leader in AI-driven antibody discovery, combining advanced computational…
Is Recursion Pharmaceuticals Setting the Standard for AI-Powered Drug Discovery with Strategic Deals and a $20B+ Partnership Pipeline?
Executive Summary Recursion Pharmaceuticals has emerged as a leading clinical-stage TechBio company applying artificial intelligence, automation, and large-scale…
Can ReviR’s AI-Powered RNA Modulation Platform Convert $50M+ in Funding into Scalable Genetic Medicines?
Executive Summary ReviR Therapeutics continues to establish itself as a leader in RNA-targeting small molecule drug discovery, advancing…
Can Ainnocence’s Causal AI Platform Redefine Drug Discovery Value as Pharma Expands AI Partnerships?
Strategic Overview Ainnocence is carving out a differentiated role in AI-driven drug discovery by emphasizing causal, mechanism-oriented artificial…
Can Generate Biomedicines—Backed by Amgen and Novartis—Redefine Biologics Discovery Through AI-Designed Protein Therapeutics?
Generate Biomedicines, Amgen and Novartis Signal Capital-Market Validation for AI-Driven Biologics Innovation The AI drug discovery sector is…
Can Insilico Medicine and China Medical System Accelerate AI-Discovered Drugs from Algorithm to Clinic?
Executive SummaryIn a strategic expansion of their collaboration in February 2026, Insilico Medicine and China Medical System Holdings…
